To our best knowledge, this is the first cost-effectiveness analysis focusing on the newly approved ICI cemiplimab for advanced NSCLC with PD-L1 of at least 50% from the United States perspective and the first to compare these 3 ICI monotherapies (pembrolizumab, atezolizumab and cemiplimab) approved as the preferred upfront therapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.